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Abstract 
Purpose: This paper studies the Quality of Life (QL) of Spanish advanced non-small-cell lung cancer (NSCLC) patients 
receiving platinum-doublet chemotherapy, compares our results with those from studies from other cultural areas, 
and identifies factors associated with global QL and survival prognostic variables.
Methods: EORTC QLQ-C30 and QLQ-LC13 questionnaires were completed three times by 39 patients along treat-
ment and follow-up. Univariate and multivariate logistic regression analyses were performed to study global QL deter-
minants (≤50 points considered low global-QL score). Analyses of prognostic variables for death were performed 
(Cox proportional hazards models).
Results: QL mean scores in the whole sample were moderately high, with limitations (>30) in physical, role, social 
functioning, emotional areas, fatigue, pain, neuropathy and global QL. Differences with studies from other cultural 
areas were mainly found in the lower score for dyspnoea (≥15 points). There were no significant differences in QL 
scores between the first and second assessments. In six areas, the third assessment was lower than the first and 
second: fatigue, hair loss (>20 points); physical, social functioning, neuropathy (10–20 points); emotional functioning 
(5–10 points). The best model to explain the chances of low QL includes, as explanatory variables, high emotional 
functioning as protective factor and fatigue as risk factor (R2 = 0.70). Eight QL areas (four pain-related) and perfor-
mance status showed a statistically significant association with survival.
Conclusion: Patients adapted well to their disease and treatments. Platinum-doublet can be administered in 
advanced NSCLC patients. Our QL data are in line with those from other cultural areas.
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Background
Lung cancer is the leading cause of cancer-associated 
mortality worldwide (Li et  al. 2012). Non-small-cell 
lung cancer (NSCLC) is more frequently diagnosed in 
advanced stages, when patients present symptoms and 
treatment side-effects that may affect their Quality of 
Life (QL; Arrieta et al. 2013). Larsson et al. (2012) found 
that before the start of treatment almost all QL areas 
(both those common to others tumours and those spe-
cifically for lung cancer) were statistically deteriorated in 
advanced NSCLC patients in comparison with the gen-
eral population.
QL assessment and improvement have a key role in 
oncology. Since the treatment of advanced NSCLC can 
have a limited effect on survival, maintaining or improv-
ing the QL of advanced NSCLC patients are considered 
important treatment goals (Wintner et al. 2013).
Braun et  al. (2011) consider that treatment for 
advanced lung cancer must always be judged in the con-
text of its effects on patient QL. In this respect, chemo-
therapy is understood that might increase survival and 
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QL in the advanced-disease non-small-cell lung cancer 
(Grønberg et  al. 2010). Platinum-based chemotherapy 
and taxanes may have a positive effect on survival and QL 
in advanced NSCLC patients with a good performance 
status (Bosch-Barrera et al. 2011; Von Plessen et al. 2006).
Larsson et al. (2012) consider that the effect of the dis-
ease and treatment on the QL of cancer patients depends 
on several factors (including the patient’s performance 
status, age, and level of fatigue) and state there is a 
need for more research on the determinants of the QL 
of advanced NSCLC patients. The role of QL as a prog-
nostic survival factor in cancer (including lung cancer) 
has been studied in recent years (Grande et  al. 2009). 
Several discrepancies have been found (Braun et  al. 
2011; Quinten et  al. 2014) that could be due to factors 
like the wide variety of QL questionnaires administered 
or including patients with different tumour sites in the 
same study. Arrieta et al. (2013) believe that the role of 
depression as a prognostic factor in NSCLC is debatable. 
Further studies on QL as a prognostic factor in NSCLC 
could prove useful. Clinical and biographical variables 
have also been studied as prognostic factors (Grønberg 
et  al. 2010). Studies of QL determinants and survival 
prediction factors in advanced disease may bring impor-
tant benefits, such as improvements in patient manage-
ment and the provision of better information (Grande 
et al. 2009).
Cross-cultural differences play a key role in important 
areas for cancer patients, such as information (Mystaki-
dou et  al. 2004) or QL: Kaptein et  al. (2011), for exam-
ple, found cross-cultural differences in the QL scores of 
NSCLC patients.
In this paper we study QL and its changes during treat-
ment and follow-up in advanced-disease NSCLC Span-
ish patients treated with platinum-doublet, compare our 
results with those from studies conducted in other cul-
tural areas, and analyse the determinants of the patients’ 
global QL as well as factors related to survival.
Methods
Participants
A consecutive sample of lung cancer patients who initi-
ated treatment at the Medical Oncology Department of 
the Complejo Hospitalario de Navarra (Spain) between 
August 2009 and June 2012 were invited to participate in 
the study.
Inclusion criteria were stage IV or stage III-B NSCLC 
[patients ineligible for curative radiotherapy according 
to the previous AJCC staging system (Mountain 1997)] 
and start of chemotherapy. The patients were treated 
with platinum-doublet (cisplatin or carboplatin depend-
ing on level of comorbidity and performance status) 
combined with taxanes, gemcitabine or pemetrexed. Not 
other systemic treatment was administered. Cycles were 
repeated every 3  weeks. Four to six cycles of platinum-
doublet were proposed for each patient. Patients with 
non-squamous histology had subsequent maintenance 
treatment with pemetrexed. Exclusion criteria were a 
cognitive state that did not permit treatment evaluation, 
a life expectancy of <3 months, a performance status <60 
[Karnosky scale (Karnofsky and Burchenal 1949)] or pos-
itive EGFR or ALK when diagnosed.
Measures
All patients completed the EORTC questionnaires QLQ-
C30 version 3.0 (Aaronson et  al. 1993) and QLQ-LC13 
(Bergman et al. 1994), which our group had validated for 
use in Spain (Arraras et  al. 2000, 2002). The structures 
of these questionnaires are shown in Table 1. QLQ-C30 
evaluates areas common to various tumour sites and 
treatments, whereas QLQ-LC13 evaluates areas associ-
ated with lung cancer and its treatments. Questionnaires 
with under 70 % of the items answered were excluded.
The treating physician assessed toxicity levels at the 
second and third assessments through selected items 
from the Common Terminology Criteria for Adverse 
Events (CTCAE) Version 4.0 (National Cancer Institute 
2009), performance status using the Karnofsky scale 
(Karnofsky and Burchenal 1949; in the three assess-
ments), and comorbidity (in the initial assessment).
Data collection procedures
Patients were invited to complete the QL questionnaires 
at three points during the treatment and follow-up peri-
ods: on the first day of chemotherapy, 2 weeks after the 
third cycle, and at the follow-up consultation 6  weeks 
after the end of the platinum-doublet treatment. Patients 
did not know the status of their disease (stable or pro-
gressing) when completing the second and third assess-
ments. Questionnaires were administered in paper pencil 
version. Patients filled in the instruments at a desk in 
the Oncology Departments. A psychologist was present 
while the questionnaires were being completed. After 
completing their questionnaires, the patients were able 
to discuss their answers with the psychologist. Patients 
did not need help to understand and to reply to the 
questions.
Ethics and consent
This study was conducted in accordance with the recom-
mendations of the Declaration of Helsinki and approved 
by the Ethics Committee of the Complejo Hospitalario 
de Navarra (Number 107/2009). Informed consent was 
obtained from all individual participants included in the 
study.
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Statistical analysis
Descriptive statistics were used to summarize the sam-
ple characteristics and the QL scores. Changes between 
the three measurements in QL scores were studied using 
the Friedman test. The Wilcoxon test with the Bonfer-
roni criteria was used to determine between which pairs 
of measurements the differences appeared. Differences 
in QL mean scores were calculated between the pairs of 
assessments that had shown statistically significant dif-
ferences after Bonferroni correction (these QL mean 
score differences were considered ‘less-than-a-little’ if the 
change was <5 points, ‘little’ if it was 5–10 points, ‘mod-
erate’ if it was 10–20, and ‘very much’ if it was >20 points; 
Osoba et al. 1998). For functional areas changes towards 
higher scores imply a QL improvement; for symptom 
areas, changes to higher scores indicate a QL decrease.
To identify which patients’ characteristics were related 
to low global QL, univariate logistic regression analyses 
were performed before the start of treatment with the 
categorized scores as response variables and sociode-
mographic (age, gender and civil status), clinical (per-
formance status and limiting comorbidity) and the other 
QL areas as explanatory variables. Here we considered a 
score ≤50 as low global QL. To complement these analy-
ses, we also used multivariate logistic regression models 
using the backward regression method and including 
those areas found to be statistically significant in univari-
ate logistic regression.
Analyses of prognostic variables were also con-
ducted. First, the relationship between the clinical and 
demographic factors (age, gender, civil status, limiting 
comorbidity, chemotherapy protocol—cisplatin or car-
boplatin—and performance status) and baseline QL, 
with overall survival (OS), was analysed (univariate Cox 
proportional hazards models). Then the QL statisti-
cally significant baseline scores and performance status 
were adjusted for gender and age. Hazard ratios were 
Table 1 Sociodemographic and  clinical characteristics of   
the sample
Characteristics No Percentage Mean SD
Present age (range 40–81) 66.1 9.9
 ≥66 years old 24 61.5
Gender
 Female 4 10.3
 Male 35 89.7
Marital status
 Single 1 2.5
 Married 36 92.3
 Widowed 2 5.2
Limiting comorbidity 19 48.7
Performance status (range 60–90)a 79.1 8.9
 60–80 26 66.7
 90 13 33.3
Stage
 IV 35 89.7
 III-B 4 10.3
Histological types
 Adenocarcinoma 18 46.2
 Large-cell carcinoma 1 2.5
 Squamous cell carcinoma 19 48.8
 Adenosquamous carcinoma 1 2.5
Chemotherapy
 Carboplatin doublet 29 74.4
 Cisplatin doublet 10 25.6
Morphine 29 74.4
2nd assessment
 Performance status (range 30–100) 70.5 17.4
Treatment response
 Progressive disease 17 43.6
 Stable disease 14 35.9
 Partial response 8 20.5
Toxicity
 Neutropenia 2 5.2
 Thrombopenia 2 5.2
 Vomiting 1 2.6
 Fatigue 1 2.6
3rd assessment
 Performance status (range 50–90) 76.8 12.1
Treatment response 3rd assessment
 Progression 7 36.8
 No changes 12 63.2
Chemotherapy cycles received (range 1–14) median 4 5.2
 Platin doublet 33 15.4
 Platin doublet + maintenance treat-
ment
6 84.6
CT from 3 to 2 weeks 3 7.7
Time-to-disease progression
 Range 0.93–17.23; median 5.20 5.98 4.54
Table 1 continued
Characteristics No Percentage Mean SD
Survival
 Range 2.20–44.63; median 7.45 10.99 8.92
a The median of the Performance status in the first measurement is presented as 
scores did not follow a normal distribution
Treatment response 2nd, 3rd assessments: treatment response at second and 
third assessment points
Toxicity: ≥3 values
Chemotherapy cycles received by those who completed the third assessments
CT from 3 to 2 weeks: patients whose CT changed from being administered 
every 3 weeks to every 2 weeks
Time to progression and survival in months
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calculated for 10-point differences in QL and perfor-
mance status scores (clinically meaningful important dif-
ference; Osoba et  al. 1998). OS was measured from the 
date of the first assessment to the date of death due to 
cancer. Patients who died due to another cause or were 
still alive at the time of analyses were censored. A p value 
≤0.05 was regarded as statistically significant in all the 
analyses performed. The SPSS 21 program was used in 
these analyses.
Results
46 patients were eligible. Three of them declined to par-
ticipate in the study. A total of 39 patients (out of 43 
initial candidates who gave informed consent) com-
pleted the first assessment. Reasons for not completing 
this assessment were death (two patients) and deriva-
tion to the palliative care unit (two patients). A total of 
34 patients completed the second assessment and 19 
patients completed the third. The reason for not com-
pleting the second assessment was disease progression 
(five patients). The reasons for not completing the third 
assessment were switches to another protocol (three 
patients) and stop the chemotherapy treatment (12 
patients: nine due to disease progression and three due to 
toxicity). The sociodemographic and clinical characteris-
tics of the patients are shown in Table 1. Mean age was 
66.1, 35 patients (89.7 %) were male, and also 35 patients 
were in stage IV. In the case of three patients, chemo-
therapy treatment (CT) passed from being administered 
every 3 weeks to every 2 weeks due to toxicity.
QL mean scores for the QLQ-C30 and the QLQ-LC13 
are presented in Table 2. Moderate QL limitations (>30) 
occurred in: emotional functioning, fatigue and global 
QL (in all three assessments); sleep disturbance (in the 
first and second assessments); physical functioning, pain 
and neuropathy (in the second assessment); and role 
and social functioning (in the second and third assess-
ments). Light QL affectations (between 20 and 29 points) 
appeared in: physical, role and social functioning, and 
pain (in the first measurement), appetite loss, constipa-
tion and coughing (in the first and second assessments); 
cognitive functioning and pain elsewhere (in the second 
assessment); dyspnoea and hair loss (in the second and 
third assessments); and physical functioning, sleep dis-
turbance and neuropathy (in the third assessment).
Eight areas (physical, emotional and social function-
ing, fatigue, dyspnoea, sore mouth, peripheral neuropathy 
and hair loss) showed differences when the three assess-
ments were compared (Table 2) but these dropped to six 
after Bonferroni correction. In all of these six areas there 
was a worse QL in the third assessment compared to the 
other two (for functional areas it implies lower scores; for 
symptom areas, higher scores). There were no significant 
differences between the first and second assessments. 
Differences between the first and the third assessment 
appeared in physical and social functioning and neuropa-
thy (moderate change) and fatigue and hair loss (very 
much change). Differences between the second and the 
third assessment appeared in physical functioning and 
fatigue (moderate change) and emotional functioning (lit-
tle change).
Table 2 Mean scores for  QLQ-C30 and  QLQ-LC13 areas 
and association with global QL
p: Level of significance Friedman test, based on complete cases only
a The scores range from 0 to 100, where a higher score represents a higher 
functional level
b The scores range from 0 to 100, where a higher score represents a greater 
degree of symptoms
1st assess-
ment
2nd assess-
ment
3rd assess-
ment
p
Mean (SD)
(N = 39)
Mean (SD)
(N = 34)
Mean (SD)
(N = 19)
QLQ-C30 areas
 Physicala 74.7 (26.5) 60.6 (32.7) 70.2 (23.7) 0.004
 Rolea 70.1 (36.9) 51.9 (37.9) 62.3 (29.8) 0.055
 Emotionala 64.1 (28.6) 57.6 (32.2) 64.9 (29.4) 0.029
 Cognitivea 82.9 (24.0) 75.0 (28.5) 80.7 (21.7) 0.146
 Sociala 76.5 (30.9) 57.8 (36.5) 64.9 (28.8) 0.004
 Globala 60.0 (25.0) 53.4 (26.8) 60.5 (21.7) 0.148
 Fatigueb 35.0 (30.4) 57.1 (56.7) 44.4 (27.9) 0.047
 Nauseab 6.4 (15.6) 7.5 (17.9) 7.0 (18.7) 0.779
 Painb 27.4 (31.6) 33.8 (36.8) 17.5 (24.5) 0.187
 Dyspnoeab 12.8 (22.4) 12.7 (18.4) 12.3 (19.9) 0.016
 Sleep distur-
banceb
34.2 (38.6) 37.2 (36.5) 22.8 (24.9) 0.933
 Appetite 
lossb
26.5 (32.6) 29.4 (36.5) 12.3 (27.8) 0.741
 Constipationb 24.8 (32.5) 28.4 (35.9) 14.1 (23.1) 0.149
 Diarrhoeab 9.5 (21.5) 3.9 (15.9) 3.1 (15.3) 0.819
 Financial 
impactb
8.5 (25) 13.7 (28.6) 0 (0) 0.607
QLQ-LC13 areas
 Coughingb 28.2 (30.1) 22.5 (26.9) 8.8 (15.1) 0.148
 Dyspnoeab 13.7 (19.9) 22.2 (23.8) 21.1 (22.5) 0.063
 Haemopty-
sisb
2.6 (8.9) 2.9 (8.6) 1.7 (7.7) 0.607
 Sore mouthb 8.5 (25.1) 18.6 (29.2) 14.0 (20.2) 0.021
 Dysphagiab 5.9 (15.1) 15.7 (28.7) 10.5 (19.4) 0.091
 Peripheral 
neuropa-
thyb
10.3 (17.4) 31.4 (14.7) 29.8 (21.9) 0.002
 Hair lossb 5.1 (19.5) 21.6 (27.1) 26.3 (21.0) 0.001
 Chest painb 10.3 (18.9) 18.6 (24.9) 12.3 (16.5) 0.641
 Pain in arm or 
shoulderb
12.8 (22.4) 14.7 (24.9) 10.5 (22.4) 0.179
 Other pain 
sitesb
18.8 (28.4) 20.2 (32.2) 3.5 (10.5) 0.247
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A statistically significant relationship was found 
between the chances of low global QL and performance 
status (p = 0.033; OR 0.91, 95 % CI 0.83–0.99, R2 = 0.19). 
No other statistically significant relationship was found 
between global QL and any of the clinical or demo-
graphic variables.
The QL areas with a statistically significant relationship 
with chances of low global QL and the highest R2 were 
role, emotional and cognitive functioning (higher val-
ues were associated with higher global QL), and fatigue, 
dyspnoea and appetite loss(higher values were associ-
ated with lower global QL; see Table 3). The multivariate 
model that best explains the chances of low global QL is 
a combination of emotional functioning as a protective 
effect (p = 0.006; OR 0.93, 95 % CI 0.88–0.98) and fatigue 
as a risk factor (p = 0.015; OR 1.06, 95 % CI 1.01–1.12; 
R2 = 70).
The results of the univariate Cox regression analyses 
indicate that performance status and ten QL areas were 
significantly associated with survival. Eight of these areas 
and performance status showed a statistically significant 
association with survival after adjustment for gender 
and age [physical functioning (p = 0.004), role function-
ing (p  =  0.022), fatigue (p  =  0.003), pain (p  =  0.002), 
appetite loss (p =  0.029), sore mouth (p =  0.008), pain 
arm or shoulder (p = 0.024), other pain sites (p = 0.005; 
Table  4)]. Four of these QL areas evaluate pain. Higher 
scores (in 10-point units) in performance status and 
functional areas (physical and role functioning) were 
associated with a lower risk of death, and higher scores in 
symptoms areas (fatigue, pain, appetite loss, sore mouth, 
pain arm or shoulder, and other pain sites) were associ-
ated with a higher risk of death.
Discussion
The main results of this study are that QL scores in a 
sample of advanced disease NSCLC Spanish patients 
treated with platinum-doublet were moderately high. In 
six QL areas there was a worse QL in the third assess-
ment compared to the other two (for functional areas it 
implies lower scores; for symptom areas, higher scores) 
and there were no significant differences between the 
latter two assessments. A logistic model with emotional 
functioning and fatigue has been created to explain the 
chances of global QL. Cox regression analyses indicated 
that performance status and eight QL areas were statis-
tically significantly associated with survival after adjust-
ment for gender and age.
The high proportion of patients (93 %) who agreed to 
participate in the study and the fact that the reasons for 
not completing the questionnaires were all medical sug-
gest that the study was feasible and well accepted by 
patients receiving treatment, and this can be regarded as 
strength of the study. Among the limitations, we should 
mention the fact that all of the patients come from the 
same hospital, the low statistical power due to: the small 
number of participants; the proportion of patients for 
whose 2nd and 3rd assessments have not been possi-
ble; and also the high number of tests done due to the 
amount of QLQ areas to be analized, which has been 
only partially corrected in the pairwise comparisons with 
the Bonferroni correction. We might consider the results 
of the present study as preliminary. It would be interest-
ing to repeat this study in other centres to try to confirm 
its results.
The demographic and clinical characteristics of the 
sample were representative of patients treated at the 
Complejo Hospitalario de Navarra.
QL scores were satisfactory if we take into account the 
advanced disease stages. The QL limitations in the first 
assessment suggest that the patients in the study were in 
a good condition to receive the treatment.
The first day of treatment scores were in line with 
those of other studies conducted with the EORTC ques-
tionnaires in NSCLC patients from other cultural areas 
in which QL had been administered just before starting 
treatment: Scandinavian countries (Larsson et al. 2012—
334 patients; Braun et al. 2011—1194 patients; Grønberg 
et al. 2010—402 patients), the Netherlands (24 patients) 
and Japan (22 patients, Kaptein et  al. 2011) and Korea 
[Park et  al. 2013—139 patients; in most of these stud-
ies the patients were at advanced disease stages (Lars-
son et  al. 2012; Braun et  al. 2011; Grønberg et  al. 2010; 
Kaptein et al. 2011)]. It is important when making these 
comparisons to take into account the limitation of the 
low sample size in our study. These scores were also in 
line with those from the EORTC reference values manual 
Table 3 QLQ-C30 and  QLQ-LC13 areas with  a significant 
relationship with the chances of low global QL
a The scores range from 0 to 100, where a higher score represents a higher 
functional level
b The scores range from 0 to 100, where a higher score represents a greater 
degree of symptoms
OR (95 % CI) R2 p value
QLQ-C30 areas
 Rolea 0.96 (0.94–0.99) 0.32 0.006
 Emotionala 0.93 (0.89–0.97) 0.53 0.001
 Cognitivea 0.95 (0.91–0.99) 0.28 0.015
 Fatigueb 1.06 (1.02–1.10) 0.46 0.002
 Painb 1.03 (1.00–1.06) 0.18 0.039
 Dyspnoeab 1.06 (1.01–1.12) 0.28 0.016
 Appetite lossb 1.04 (1.01–10.07) 0.28 0.011
QLQ-LC13 areas
 Coughingb 1.03 (1.00–1.06) 0.19 0.030
 Dyspnoeab 1.08 (1.02–1.15) 0.33 0.016
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for NSCLC at various stages (Scott et al. 2008). Patients 
in our study showed less dyspnoea (≥15 points) than 
those in the six above studies and the EORTC reference 
values. This could be due to the morphine-based treat-
ment. Limitations in fatigue were moderate but lower 
(≥10 points) than in NSCLC Scandinavian patients at the 
same (Larsson et al. 2012; Grønberg et al. 2010) disease 
stages.
No significant changes were found between the first 
day of treatment and during-treatment assessments. 
Few changes appeared between the third and the first 
two assessments, mainly in treatment-related areas. 
These results are in line with those of other studies con-
ducted with the EORTC questionnaires. Wintner et  al. 
(2013) found no significant QL changes during the CT 
period in Austrian advanced lung-cancer patients. Von 
Table 4 Univariate Cox regression analyses of survival at base line
HRs hazard ratios, CI confidence interval
a Unadjusted: Univariate Cox proportional hazards models
b Adjusted: Univariate Cox proportional hazards models adjusted for gender and age
c The scores range from 0 to 100, where a higher score represents a higher functional level
d The scores range from 0 to 100, where a higher score represents a greater degree of symptoms
Explanatory variables Unadjusteda Adjustedb
HR (95 % CI) p HR (95 % CI) p
Socio-demographic and clinical variables
 Age (continuous) 0.98 (0.95–1.01) 0.282
 Gender (male vs. female) 1.92 (0.66–5.56) 0.229
 Civil status (married vs. other status) 0.97 (0.29–3.20) 0.966
 Limiting comorbidity (yes vs. no) 1.13 (0.71–2.40) 0.386
 Chemotherapy protocol (carboplatin vs. cisplatin) 0.65 (0.32–1.13) 0.230
 Performance status (continuous) 0.95 (0.92–0.99) 0.018 0.59 (0.39–0.88) 0.010
QLQ-C30 areas
 Physicalc 0.83 (0.72–0.96) 0.011 0.81 (0.71–0.93) 0.004
 Rolec 0.86 (0.77–0.96) 0.006 0.87 (0.77–0.99) 0.022
 Emotionalc 0.96 (0.87–1.11) 0.804 1.01 (0.88–1.17) 0.853
 Cognitivec 0.85 (0.73–0.99) 0.044 0.88 (0.73–1.06) 0.169
 Socialc 0.91 (0.82–1.01) 0.099 0.93 (0.82–1.06) 0.268
 Globalc 0.90 (0.76–1.06) 0.210 0.88 (0.73–1.07) 0.203
 Fatigued 1.25 (1.09–1.43) 0.002 1.25 (1.08–1.44) 0.003
 Nausead 1.08 (0.97–1.34) 0.490 0.93 (0.67–1.31) 0.697
 Paind 1.26 (1.20–1.44) 0.001 1.26 (1.09–1.45) 0.002
 Dyspnoead 1.03 (0.90–1.18) 0.620 1.04 (0.90–1.19) 0.602
 Sleep disturbanced 0.99 (0.92–1.08) 0.939 1.01 (0.92–1.11) 0.818
 Appetite lossd 1.14 (1.03–1.26) 0.008 1.13 (1.10–1.27) 0.029
 Constipationd 1.03 (0.95–1.13) 0.422 1.03 (0.94–1.14) 0.495
 Diarrhoead 1.01 (0.86–1.18) 0.930 1.04 (0.89–1.22) 0.607
 Financial impactd 1.19 (1.03–1.37) 0.019 1.16 (0.99–1.34) 0.600
QLQ-LC13 areas
 Coughingd 1.01 (0.91–1.14) 0.755 1.02 (0.91–1.15) 0.709
 Dyspnoead 1.17 (0.97–1.42) 0.104 1.14 (0.94–1.39) 0.191
 Haemoptysisd 1.37 (0.94–1.98) 0.099 1.39 (0.95–2.03) 0.090
 Sore mouthd 1.25 (1.05–1.49) 0.010 1.27 (1.06–1.52) 0.008
Dysphagiad 1.16 (0.94–1.43) 0.167 1.19 (0.97–1.47) 0.099
 Peripheral neuropathyd 1.04 (0.86–1.27) 0.655 1.04 (0.85–1.27) 0.702
 Hair lossd 1.08 (0.92–1.25) 0.355 1.07 (0.91–1.25) 0.434
 Chest paind 1.07 (0.89–1.29) 0.425 1.02 (0.85–1.23) 0.815
 Pain in arm or shoulderd 1.19 (1.01–1.40) 0.034 1.22 (1.03–1.45) 0.024
 Other pain sitesd 1.18 (1.03–1.33) 0.012 1.20 (1.06–1.36) 0.005
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Plessen et al. (2006) found a worsening in the third assess-
ment compared to the first in fatigue (moderate change) 
and global QL (little change) in Scandinavian advanced 
NSCLC patients. Park et al. (2013) also found few changes 
in the third assessment compared to the first in early-
stage NSCLC Korean patients who had received adjuvant 
CT (neuropathy and hair loss; very much change).
The QL scores in each assessment, the low number of 
changes in these QL scores, the low number of patients 
who did not complete the second assessment, the low 
number of patients who reduced CT dose (from 3-week 
cycles to 2-week cycles), and the low toxicity scores sug-
gest that toxicity control was satisfactory.
Performance status was found to be a determinant of 
global QL in other studies of advanced NSCLC patients 
(Larsson et  al. 2012) and lung cancer patients(NSCLC 
and small cell lung cancer) at various disease stages 
(Mohan et al. 2007).
Fatigue and emotional functioning were found to be 
key determinants of global QL in other studies conducted 
with the EORTC questionnaires. Ostlund et  al. (2007) 
found that a combination of emotional functioning and 
fatigue was the main global QL determinant in lung can-
cer patients (at a variety of disease stages). Arrieta et al. 
(2013) also found that emotional functioning was associ-
ated with global QL in advanced NSCLC patients. Emo-
tional functioning (Cramarossa et  al. 2013) and fatigue 
(Beijer et al. 2008) were found to be important determi-
nants of global QL in advanced disease cancer patients 
with different tumor sites.
Ostlund et  al. (2007) suggest that low emotional 
functioning can influence global QL scores because it 
includes negative thoughts than can be reference points 
for patients when assessing their QL. Fatigue is consid-
ered to have a major impact on the QL of cancer patients 
because it includes physical, emotional and cognitive 
dimensions (Weis et al. 2013) that can affect every aspect 
of the patient’s daily life (Ostlund et al. 2007).
Performance status was found to be a predictor of sur-
vival in other studies with NSCLC patients at the same 
disease stages as those in our study (Ediebah et al. 2014), 
and at a variety of stages (Li et al. 2012).
Age was not a predictive factor in our study, in other 
studies of NSCLC patients at the same stages of disease 
(Arrieta et  al. 2013; Ediebah et  al. 2014) or in a review 
of studies of lung cancer patients (Quinten et  al. 2014). 
Braun et al. (2011), on the other hand, found age to be a 
predictive factor in NSCLC patients at a variety of stages 
(though their age range was wider).
Comorbidity was not found to be a predictive factor in 
other studies of patients with advanced NSCLC (Grøn-
berg et al. 2010; Bergman et al. 1994; Maione et al. 2005). 
Grønberg et  al. (2010) consider comorbidity to be a 
predictive factor of survival in NSCLC at early stages but 
that this has not been confirmed at advanced stages when 
patients may die of cancer before they die from their 
other illnesses. Comorbidity has been assessed in other 
studies performed in NSCLC patients with the Simplified 
Comorbidity Score (SCS; Colinet et al. 2005). This instru-
ment has shown to predict survival in NSCLC patients in 
different disease stages, and might be used in future stud-
ies with just advanced NSCLC patients to assess its role 
as predictive factor.
Our results on QL as predictive factors are in line with 
those of other studies in which the EORTC question-
naires were administered. Physical, role functioning, 
fatigue and pain (in our case also in the pain areas of the 
QLQ-LC13) were also found to be predictive factors in 
advanced NSCLC patients (Grande et  al. 2009; Ediebah 
et al. 2014) and at a variety of stage (Li et al. 2012; Braun 
et  al. 2011). Limitations in these four areas could be a 
consequence of disease progression.
Appetite loss was found to be a predictor of survival in 
advanced NSCLC patient (Grande et al. 2009) at a vari-
ety of stages (Li et al. 2012; Braun et al. 2011). Appetite 
loss may be a predictive factor as it could be part of the 
anorexia-cachexia syndrome that frequently appears in 
advanced lung cancer patients (Del Ferraro et al. 2012).
Cognitive functioning was not found to be a predictor 
of survival. This could be because patients with cognitive 
limitations were excluded from the study.
Global QL was not found to be a predictive factor in 
our study or in that of Grande et al. (2009) with advanced 
NSCLC patients. However, it was in other NSCLC stud-
ies at a variety of stages (Li et al. 2012; Braun et al. 2011). 
A larger sample could provide more solid conclusions.
Nausea and vomiting, diarrhea, neuropathy and hair 
loss were not found to be predictors. These variables may 
be related to treatment side effects. Emotional function-
ing, sleep disturbance, constipation, financial impact and 
chest pain were not found to be predictors in studies 
conducted with advanced NSCLC patients (Grande et al. 
2009; Ediebah et al. 2014).
Scores for dyspnoea, haemoptysis and dysphagia were 
low in our sample, which could explain why they were 
not predictive factors. Coughing was not a predictive fac-
tor in studies with NSCLC patients at various stages (Li 
et al. 2012).
Conclusions
Advanced Spanish NSCLC patients treated with plati-
num-doublet showed moderate QL scores during treat-
ment and follow-up assessments. When studying the 
patients who have filled in the three assessments, their 
QL scores were worse in the third assessment, which 
indicates that the patients adapted well to their disease 
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and treatment. QL and clinical data suggest that plati-
num-doublet can be administered in advanced NSCLC 
patients. Our QL data are in line with those from other 
cultural areas.
Longitudinal QL assessments are important in 
advanced lung cancer patients because the data they pro-
vide could, for example, help to assess more patient areas 
and enable early recognition of arising symptom aggra-
vation, thus leading to more efficient and more timely 
interventions (Wintner et al. 2013).
In this study the QL factors related to global QL and 
survival we have identified are in line with those found 
in other studies. Further research could help to assess 
what role the management of QL determinants and QL 
survival prognostic factors could play in the treatment of 
cancer patients (Arrieta et al. 2013).
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